Intercell AG

EANS-Adhoc: Intercell Executes Multi-Year Contract for Supply of IXIARO® to the United States Military

@@start.t1@@--------------------------------------------------------------------------------   ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide   distribution. The issuer is solely responsible for the content of this   announcement. --------------------------------------------------------------------------------@@end@@

Company Information

08.05.2009

» Exclusive, multi-year contract executed by Intercell and   U.S. Department of Defense for purchase of IXIARO®

» First sales of IXIARO under this military contract expected soon

Vienna (Austria), May 8, 2009 - Intercell AG (VSE: ICLL) announced today that the Company has successfully entered into a multi-year contract with the Defense Logistics Agency (DLA), Defense Supply Center of the U.S. Department of Defense to supply IXIARO, a vaccine against Japanese Encephalitis (JE). The first sales of IXIARO under this contract are expected in the near future. This supply contract was negotiated in response to a Request for Proposals (RFP) issued by the DLA in August 2008. The parties were able to move forward to finalize the contract after IXIARO was approved by the Food and Drug Administration on March 30.

The major terms of this contract are as follows: » Exclusive contract for Intercell to supply DLA with all their   requirements for JE vaccine » Five-year contract, with annual options for price modifications

"With a mortality rate that can exceed 30 percent, Japanese Encephalitis is a clear danger to the thousands of military personnel - and their families - that are stationed in areas where the disease is endemic. IXIARO will provide a new level of protection for this group of people at risk," stated Gerd Zettlmeissl, Chief Executive Officer of Intercell. "Intercell is very pleased that the Department of Defense has acknowledged the value of IXIARO by entering into a long-term supply agreement."

IXIARO was developed by Intercell under an agreement with the Walter Reed Army Institute of Research (WRAIR). JE is a very serious and growing public health threat in Asia. The U.S. military plans to use IXIARO to protect its troops, families and contract workers who are deployed to affected countries. Intercell will directly distribute and market IXIARO to the U.S. military. Novartis Vaccines USA will market and distribute the vaccine to the private market in the U.S.

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Index:    ATX Prime, ATX
Börsen:  Wien / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: